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BACKGROUND
Screening mammography (MMG) is the only diagnostic method
that has been proven

by numerous randomized studies and meta-
analyses of those studies

to be effective in reducing the mortality
rate by breast cancer screening (1, 2). However, in recent years,
the usefulness of MMG screening has been called into question
(3, 4). For example, it was reported that, even when early cancers
were detected by screening MMG, subsequent follow-up studies
found that advanced cancers were only marginally reduced. It was
concluded that “screening is having, at best, only a small effect on
the rate of death from breast cancer” (5). On the other hand, it has
been argued that the balance between the benefits and harms of
screening is important (2, 6 -8). In the 2009 screening mammogra-
phy guidelines of the US Preventive Services Task Force (USPSTF),
the recommendation for breast cancer screening of women aged
40~49 years has been changed from grade B to grade C (9). The
reason is that, for that age group, comprehensive evaluation of the
benefit (reduction of mortality) and harms (radiation exposure,
pain, anxiety, overdiagnosis, and false-negative and false-positive
results) showed that the net benefit was small. One of those harms,
i.e., overdiagnosis, is defined as “some screening-detected cancers
may never progress to be symptomatic in the absence of screening,
and some women might die from another cause before the cancer
becomes evident” (6).
The introduction of MMG to breast cancer screening brought
about a sharp increase in the detection of ductal carcinoma in situ
(DCIS). However, invasive ductal carcinoma (IDC) accounts for
about 14~50% of DCIS (10, 11), and it can be thought that much
of the abovementioned overdiagnosis in breast cancer screening is
due to diagnosis of harmful DCIS that does not lead to IDC. Meta-
analysis regarding overdiagnosis reportedly showed overdiagno-
sis of about 11% to 19% in the subject group undergoing screening
MMG (6). In Japan, consideration is now being given to combined
use of both MMG and ultrasonography for breast cancer screening
(7), raising concern that it might lead to even more overdiagnosis.
DCIS is a diverse group of diseases, and it will be necessary to
identify (low-grade) DCIS (LGD) in order to reduce overdiagnosis
in screening. There have been a few reports regarding assessment
of the degree of malignancy of DCIS based on the molecular biol-
ogy characteristics (12, 13), but there have been no reports that
focused on LGD. Moreover, there is no consensus regarding
judgment criteria for DCIS based on the ER, PgR and HER2 im-
munostaining commonly used in clinical medicine, and evaluation
of malignancy in DCIS by immunostaining has not been estab-
lished. Accordingly, we investigated whether it would be possible
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to focus on LGD and apply our experience-based findings for the
pathological and immunohistological biomarkers of DCIS in order
to identify DCIS having a strong possibility of becoming LGD.
In order to identify image findings characteristic of LGD, we also
performed a retrospective re-examination of MMG and ultrasound
images of DCIS.
MATERIALS AND METHODS
The subjects of the study were 169 Japanese women who were
treated at Tokushima Breast Care Clinic between April 1998 and
September 2010. Cases of male breast cancer, bilateral breast can-
cer and cases of micro- invasion were excluded. Tissue specimens
from all the cases were subjected to HE staining and immunostain-
ing for ER, PgR, HER2 and Ki67, and a physician specializing in
mammary gland pathology performed the pathological diagnosis
and assessed the immunostaining results. The antibodies used for
the immunostaining were 1D5 (Dako) (dilution : 1 : 50 ; pretreat-
ment : boiling (pH 9.0, 40 min)) for ER ; PgR 636 (Dako) (dilu-
tion : 1 : 800 ; pretreatment : boiling (pH 9.0, 40 min)) for PgR ;
HercepTestTM (Dako) for HER2 ; and MIB-1TM (Dako) (dilution :
1 : 50 ; pretreatment : autoclaving) for Ki67. The staining method
was the same as the usual method used for invasive cancer. For ER
and PgR, the specimen was judged to be positive when1% of the
cancer cells were stained positively. HER2 staining was judged by
the usual method, using scores from 0 to 3+, and scores of 2+ and
3+ were considered positive. Ki67 was judged by using a counting
grid to inspect at least 100 tumor cells and then calculating the
percentage of positively stained cells to obtain the staining rate.
Specimens were classified into four subtypes based on the expres-
sion of ER and HER2 : ER(+)/HER2(-), ER(+)/HER2(+), ER(-)/
HER2(-) and ER(-)/HER2(+).This study was approved by the Eth-
ics Committee of the University of Tokushima.
This study focused on identifying LGD. The Ki67 index was used
to judge the grade of malignancy, and in order to confirm the reli-
ability of that, we investigated the relationship between the index
and the nuclear grade (NG), with/without comedo necrosis. Next,
we examined the relationships of each ER/HER2 subtype and the
NG, with/without comedo necrosis, with the grade of malignancy.
Then we examined the relationships of each subtype to the MMG
and ultrasound imaging findings. The MMG findings were classi-
fied as microcalcification (MC) yes/no, while high-density shad-
ows were classified as a tumor shadow, focal asymmetric density
(FAD), distortion or no findings (NF). The ultrasound imaging
findings were classified in accordance with the Guidelines for Breast
Ultrasound-Management and Diagnosis, 3rd Edition (revised ; ed-
ited by the Japan Association of Breast and Thyroid Sonology).
That is, mass or non-mass lesions were classified as a solid mass,
cystic lesion (cystic or mixed), hypoechoic area, duct-dilatation or
NF, while high-echo spots suspected of being MC were classified
as MC yes or MC no.
Statistical analysis
The χ2 or Fisher’s exact test was used for comparisons between
categorical variables. Differences in mean values between sub-
groups were tested with the Mann-Whitney U test. Multiple group
comparisons were performed using the Kruskal -Wallis test fol-
lowed by the Steel -Dwass post -hoc test. Differences were assessed
with a 2-sided test and considered significant at the P0.05 level.
RESULTS
1. Patient background
The patients ranged in age from 29 to 93 y (mean : 57.5 y ;
median : 58 y), with a distribution of 32.0% aged49 y and 68.0%
aged50 y. The rates of NG 1, 2 and 3 were 28.4%, 58.0% and
13.6%, while the rates of with comedo necrosis and without comedo
necrosis were 65.1% and 34.9%. The positive and negative rates
were 82.8% and 17.2% for ER, 74.6% and 25.4% for PgR, and 23.1%
and 76.9% for HER2 (Table 1). Based on imaging findings of cate-
gory 3 and higher, 147 (87.0%) patients had both MMG and ultra-
sonic findings, one patient had only MMG findings and 19 (11.2%)
patients had only ultrasonic findings (dates were not shown). The
breakdown of the findings showed, for the MMG findings, 92
(54.4%) patients with MC yes, while for the high density shadows,
38 (22.5%) patients had a tumor shadow, 28 (16.6%) patients had
FAD, 3 (1.8%) patients had distortion and 100 (59.2%) patients had
NF. In the ultrasonic findings, for mass or non-mass lesions, 60
(35.5%) patients had a solid mass, 12 (7.1%) patients had a cystic
lesion, 69 (40.8%) patients had a hypoechoic area, 6 (3.6%) patients
had duct dilatation, and 22 (13.0%) patients had NF. High-echo
spots suspected of being MC were classified as ‘yes’ for 78 (46.2%)
patients (Table 2).
2. Relationship between Ki67 index and NG, with/without com-
edo necrosis
Using 15% as the cut-off for the Ki67 index, we classified speci-
mens into low and high groups and investigated the relationship
between the Ki67 index and NG, with/without comedo necrosis.
The results showed a statistically significant correlation between
the Ki67 index low/high and NG, with/without comedo necrosis
(Table3).
3. Relationship between Ki67 index and NG
Detailed examination of the relationship between the Ki67 index
and NG was performed, and the Ki67 indexes with NG 1, NG 2 and
NG 3 were 8.388.76, 8.828.65 and 25.1718.26. The Ki67 index
with NG 3 was significantly larger than with the other NG groups
(p0.0001). The difference between NG 1 and NG 2 was not sig-
nificant (Fig. 1).
4. Ki67 indexes with each subtype, with/without comedo necrosis
The number of patients with each subtype were 117 (69.2%) with
ER(+)/HER2(-), 23 (13.6%) with ER(+)/HER2(+), 13 (7.7%) with
ER(-)/HER2(-) and 16 (9.5%) with ER(-)/HER2(+) (Table 1). The
respective Ki67 indexes were 7.457.10, 15.0812.28, 21.31
21.48 and 21.8115.95 (meanSD). The Ki67 index with ER(+)/
HER2(-) was significantly lower than with each of the other types.
In regard to with/without comedo necrosis, the numbers of ER(+)/
HER2(-) type patients with necrosis and without necrosis were
both about 50%, but for each of the other types almost all of the
patients were ‘with necrosis’ (Fig. 2). These results indicate that
the ER(+)/HER2(-) type is clearly different from the other three
types.
5. Ki67 indexes for the ER(+)/HER2(-) type, with/without com-
edo necrosis
We investigated the Ki67 indexes with the ER(+)/HER2(-) type,
with/without comedo necrosis. The Ki67 index with comedo ne-
crosis (n=65, 38.5%) was 8.856.96, while without comedo necrosis
(n=52, 30.8%) it was 5.716.94. The Ki67 index was significantly
lower in the case of without comedo necrosis (p0.01). Also, the
distribution of the Ki67 indexes showed a single peak in the case
of without comedo necrosis, whereas it showed two peaks in the
case of with comedo necrosis (Fig. 3).
Based on these results, we predicted that the ER(+)/HER2(-)
type without comedo necrosis is clearly LGD compared with the
other types. Hereinafter, in this paper, we defined the ER(+)/
HER2(-) type without comedo necrosis as LGD.
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Table 1. Various clinicopathological factors in patients with DCIS
N (%)
Case No Total 169 (100.0)
Age (y)
Median, range
49
50
58, 29 -93
54
115
(32.0)
(68.0)
Nuclear grade
1
2
3
48
98
23
(28.4)
(58.0)
(13.6)
Comedo necrosis WithoutWith
59
110
(34.9)
(65.1)
ER NegativePositive
29
140
(17.2)
(82.8)
PgR NegativePositive
43
126
(25.4)
(74.6)
HER2 NegativePositive
130
39
(76.9)
(23.1)
Subtype
ER(+)HER2( -)
ER(+)HER2(+)
ER(-)HER2( -)
ER( -)HER2(+)
117
23
13
16
(69.2)
(13.6)
(7.7)
(9.5)
Ki -67 Low (
15%)
High (15%)
126
43
(74.6)
(25.4)
ER(+)HER2( -)
with/without comedo
necrosis
Yes
No
52
117
(30.8)
(69.2)
DCIS : ductal carcinoma in situ ; MC : microcalcification ; ER : estrogen receptor ; PgR : proges-
terone receptor
Table 3. Relationship between subtypes of DCIS and findings of mammography or ultrasonography
M
am
m
og
ra
ph
y
Subtype N
MC High-density shadow
No
(%)
Yes
(%) P
Tumor
shadow
(%)
FAD
(%)
Distortion
(%)
No findings
(%) P
Total 169 77 (45.6) 92 (54.4) 38 (22.5) 28 (16.6) 3 (1.8) 100 (59.2)
ER(+)/HER2( -) 117 66 (56.4) 51 (43.6)
0.0001
36 (30.8) 19 (16.2) 2 (1.7) 60 (51.3)
0.0001
ER(+)/HER2(+) 23 1 (4.3) 22 (95.7) 2 (8.7) 0 (0.0) 1 (4.3) 20 (87.0)
ER(-)/HER2( -) 13 7 (53.8) 6 (46.2) 0 (0.0) 6 (46.2) 0 (0.0) 7 (3.8)
ER(-)/HER2(+) 16 3 (18.8) 13 (81.3) 0 (0.0) 3 (18.8) 0 (0.0) 13 (81.3)
U
ltr
as
on
og
ra
ph
y Subtype N
Mass or non-mass lesion High-echo spots (MC)
Solid
mass
(%)
Cystic
lesion
(%)
Hypo-
echoic area
(%)
Duct -
dilatation
(%)
No
findings
(%)
P
No
(%)
Yes
(%) P
Total 169 60 (35.5) 12 (7.1) 69 (40.8) 6 (3.6) 22 (13.0) 91 (53.8) 78 (46.2)
ER(+)/HER2( -) 117 51 (43.6) 12 (10.3) 41 (35.0) 3 (2.6) 10 (8.5)
0.0018
74 (63.2) 43 (36.8)
0.0001
ER(+)/HER2(+) 23 4 (17.4) 0 (0.0) 12 (52.2) 0 (0.0) 7 (30.4) 1 (4.3) 22 (95.7)
ER(-)/HER2( -) 13 4 (30.8) 0 (0.0) 7 (53.8) 1 (7.7) 1 (7.7) 10 (76.9) 3 (23.1)
ER(-)/HER2(+) 16 1 (6.3) 0 (0.0) 9 (56.3) 2 (12.5) 4 (25.0) 6 (37.5) 10 (62.5)
The χ2 or Fisher’s exact test was used to determine the associations between categorical variations.
DCIS : ductal carcinoma in situ ; MC : microcalcification
ER : estrogen receptor ; HER2 : human epidermal growth factor type 2 ; FAD : focal asymmetric density
Table 2. Relationship between Ki67 index, nuclear grade and comedo necrosis in patients with DCIS
N (%)
Nuclear grade (NG) Comedo necrosis
1 (%) 2 (%) 3 (%) P Without (%) With (%) P
Total 169 48 (28.4) 98 (58.0) 23 (13.6) 59 (34.9) 110 (65.1)
Ki67 index
Low (15%) 126 (74.6) 39 (81.3) 81 (82.7) 6 (26.1)
0.0001
53 (89.8) 73 (66.4)
0.0008
High (15%) 43 (25.4) 9 (18.8) 17 (17.3) 17 (73.9) 6 (10.2) 37 (33.6)
DCIS : ductal carcinoma in situ
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6. Imaging findings with each subtype
The imaging findings were compared among the subtypes. In
the MMG findings, detection of MC differed significantly among
the subtypes (p0.0001). In particular, more than half of the ER(+)/
HER2(-) type cases had no MC, whereas almost all of the HER2(+)
cases had MC. In the density findings 100 (59.2%) of the 169 pa-
tients had no findings. Thirty -six (94.7%) of 38 patients showing a
tumor shadow were the ER(+)/HER2(-) type. On the other hand,
19 (67.8%) of 28 patients showing findings of FAD were the ER(+)/
HER2(-) type. Next, we compared the ultrasound findings among
the subtypes. For mass or non-mass lesions, the 117 ER(+)/
HER2(-) type patients showed incidences of 43.6% for solid masses,
10.3% for cystic lesions and 35% for hypoechoic areas, whereas the
other types were clearly different in that they showed an incidence
of 50% or more for hypoechoic areas. Also, 51 (85%) of 60 patients
with findings of a solid mass were the ER(+)/HER2(-) type, while
all 12 patients with findings of a cystic lesion were also the ER(+)/
HER2(-) type. Moreover, high-echo spots suspected of being MC
were not detected in more than half of the ER(+)/HER2(-) type
patients, but they were detected in most of the HER2(+) patients.
There was thus a clear, significant difference between the subtypes
(p0.0001) (Table 3). Moreover, the imaging findings character-
istic of LGD were the absence of MC in the MMG findings, and,
in the ultrasound findings, either the presence of a solid mass or
cystic lesion, or the absence of hypoechoic areas (Table 4).
DISCUSSION
Most overdiagnosis by breast cancer screening is thought to be
DCIS. DCIS is said to comprise about 2~5% of symptomatic breast
carcinomas (6). It is said that, since the introduction of mammogra-
phy, from 20% to about half of the discovered cancers are DCIS (6).
Figure 1. Relationship between the Ki67 index and the nuclear grade
(NG) in the total cases
The cases were classified into subtypes based on the results of immunostain-
ing for expression of ER and HER2. The horizontal bar shows the mean
values for each group. The P values show the results of application of the
Kruskal -Wallis test (P=8.3110 - 6), followed by the Steel -Dwass test.
ER : estrogen receptor ; HER2 : human epidermal growth factor type2
Figure 2. The Ki67 indexes for eachsubtype classified by the expres-
sion of ER and HER2
With/without comedo necrosis are shown for each subtype. The hori-
zontal bar shows the meanvalues for each group. The P values show the
results of application of the Kruskal -Wallis test (P=3.0110 - 6), followed
by the Steel -Dwass test.
ER : estrogen receptor ; HER2 : human epidermal growth factor type2
Figure 3. Relationship between the Ki67 indexes and each ER(+)/
HER2( -) type, with/without comedo necrosis
The horizontal bar shows the mean values for each group. The P values
show the results of application of the Mann-Whitney test.
ER : estrogen receptor ; HER2 : human epidermal growth factor type 2
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However, DCIS is a heterogeneous disease population, and the
grade of the malignancy must be taken into consideration (14-16).
In this study, we used the Ki67 index to judge the grade of ma-
lignancy. The diagnostic value of the Ki67 index for grading the
malignancy of DCIS has been controversial (17). However, we
think that we confirmed the reliability of the Ki67 index for that
evaluation because we were able to demonstrate a significant cor-
relation between it and NG, with/without comedo necrosis. First,
we investigated the grade of DCIS on the basis of the pathological
findings. The results showed no difference between NG 1 and
NG 2, while only NG 3 showed a high grade. Also, both NG 1 and
NG 2, with comedo necrosis, showed a high grade of malignancy.
All cases of NG 3 had necrosis. Therefore, pathologically, both
NG 1 and NG 2, without comedo necrosis, showed a statistically
significant low grade of malignancy. Various studies investigated
the risk of recurrence following breast-conserving treatment of
DCIS and reported that there was no difference between low-grade
and intermediate-grade malignancy (18) ; that NG was a better
predictor of recurrence than comedo necrosis (19) ; and that NG
was the most important factor in regard to recurrence of DCIS (20).
Although comedo necrosis has less effect than NG, it is considered
to be a weak risk factor (21). It was also reported that, in cases of
high NG, the presence or absence of comedo necrosis was not a
risk factor (22). The above findings were in general agreement with
our present results.
We next investigated the grade of malignancy in regard to bio-
markers. At present, there are still no definitive judgment criteria
for the results of immunostaining for ER, PgR and HER2. For our
study, we used a criterion of1% for ER and PgR immunopositivity,
since in recent years this has been used as the criterion for posi-
tivity of these markers in invasive carcinoma (23). Meijinen et al.
also considered any positive staining result to be the criterion for
ER positivity in DCIS (24). On the other hand, we judged HER2
staining to be positive when it was 2+ or 3+, in accordance with the
criteria of Kerlikowske et al. (25). Thus, we did not investigate
cases of 2+ by FISH, etc. Our results showed that the ER(+)/
HER2(-) type accounted for approximately 70% of all DCIS, that its
Ki67 index was significantly lower than for the other types, and
that it was a low-grade malignancy. Moreover, the ER(+)/HER2(-)
type without comedo necrosis accounted for about 30% of the total
cases of DCIS, and its grade of malignancy was significantly lower
than that of the ER(+)/HER2(-) type with comedo necrosis. We
considered the ER(+)/HER2(-) type without comedo necrosis to
be the most harmful population within DCIS, i.e., LDG. Moreover,
it was indicated that the ER(+)/HER2(-) type with comedo necro-
sis might include a mixture of two DCIS types, one with the same
characteristics as without comedo necrosis and a second with a
slightly higher grade of malignancy.
A biomarker-based study of the risk of local recurrence follow-
ing breast-conserving treatment of DCIS found that high levels of
expression of p16, COX-2 and Ki67 were significant risk factors
(25, 26). Moreover, with regard to ER, HER2 and Ki67, ER(-),
HER2(+) and Ki67(+) were reported to be risk factors (25). The
results of immunohistochemical studies of 314 DCIS patients showed
that there were significantly many cases of local recurrence in the
higher tumor grade, positive margin status, luminal B, HER2(+)
groups. Moreover, the ER(-)/HER2(+) group was the type with
the most recurrence, while the luminal A type had fewer cases of
recurrence (27). Our findings are in agreement with those results.
In addition, HER2(+) and Ki67 were reported to be risk factors that
are independent of the nuclear grade and patient age (28).
Next, in our investigation for possible relationships between
the imaging findings and the subtypes, we found that more than
half of ER(+)/HER2(-) type cases were MC no, whereas almost all
HER2(+) type cases were MC yes. Detection of MC was significantly
different between these subtypes. Moreover, for the ultrasound
findings, the results showed that the ER(+)/HER2(-) type was sig-
nificantly more common in cases with solid mass or cystic lesion.
Also, the imaging findings characteristic of LGD were the absence
of MC in the MMG findings, and, in the ultrasound findings, either
the presence of a solid mass or cystic lesion, orthe absence of hy-
poechoic areas.
The cases we studied included DCIS detected by ultrasound.
Approximately 80% of breast cancers detected by screening in
Europe and the USA are detected by MMG, and most cases of DCIS
were detected by MC in the MMG findings (29). In Japan, on the
other hand, ultrasound examinations are becoming more com-
monly performed on an outpatient basis. In our patient cohort, as
well, DCIS was discovered in 19 (11.2%) patients on the basis of
only ultrasound findings, which far exceeds the single case that
was detected only on the basis of MMG findings. If we consider the
fact that, in our present results, the case of MC yes detected by
MMG was DCIS with a significantly high degree of malignancy,
then it indicates that many cases of low-malignancy DCIS are being
detected by ultrasonography in Japan. That can also be surmised
from the fact that, in our present cases, the ER(+)/HER2(-) type
Table 4. Relationship between ER(+)/HER2( -)comedo necrosis( -) group of DCIS and findings of mammography or ultrasonography
M
am
m
og
ra
ph
y ER(+)/HER2( -)
Without
comedo necrosis
N
MC Density
No
(%)
Yes
(%) P
Tumor
shadow
(%)
FAD
(%)
Distortion
(%)
No
findings
(%)
P
Total 169 77 (45.6) 92 (54.4) 38 (22.5) 28 (16.6) 3 (1.8) 100 (59.2)
Yes 52 42 (80.8) 10 (19.2)
0.0001
23 (44.2) 9 (17.3) 1 (1.9) 19 (36.5)
0.0001
No 110 35 (29.9) 82 (70.1) 15 (12.8) 19 (16.2) 2 (1.7) 81 (69.2)
U
ltr
as
on
og
ra
ph
y ER(+)HER2( -)
Without
comedo necrosis
N
Mass or non-mass lesion High-echo spots (MC)
Solid mass
(%)
Cystic
lesion
(%)
Hypo-
echoicarea
(%)
Duct -
dilatation
(%)
No
findings
(%)
P
No
(%)
Yes
(%) P
Total 169 60 (35.5) 12 (7.1) 69 (40.8) 6 (3.6) 22 (13.0) 91 (53.8) 78 (46.2)
Yes 52 31 (59.6) 8 (15.4) 10 (19.2) 1 (1.9) 2 (3.8)
0.0001
46 (88.5) 6 (11.5)
0.0001
No 117 29 (24.8) 4 (3.4) 59 (50.4) 5 (4.3) 20 (17.1) 55 (47.0) 72 (61.5)
The χ2 or Fisher’s exact test was used to determine the associations between categorical variations.
DCIS : ductal carcinoma in situ ; MC : microcalcification
ER : estrogen receptor ; HER2 : human epidermal growth factor type 2 ; FAD : focal asymmetric density
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comprised 69.2% of the total DCIS cases, which is a clearly higher
incidence than the 54.6% rate reported by Meijnen et al. for the
Netherlands (30). Moreover, the previously noted results of meta-
analysis of overdiagnosis showed an overdiagnosis rate of 11% to
19%. On the other hand, our present rate of LGD (that is, cases
with high potential for overdiagnosis) was 30.8%. Although those
two data cannot be directly compared, we can readily conclude
that this incidence of LGD is high, which also suggests that many
cases of low-grade DCIS are being detected in Japan. In addition,
there is a possibility that cases of LGD are also included in the
ER(+)HER2(-) type with comedo necrosis, which permits us to
estimate that around half of DCIS cases in Japan are a result of
overdiagnosis. Introduction of breast cancer screening that em-
ploys ultrasonography is now being considered in Japan (7), but
there is concern that this will even further increase detection of
LGD. There is also the risk that false-positives will increase. The
handling of BI-RADS MMG findings has been changed so that
detailed examinations would be necessary only for IDC and high-
grade DCIS. It is thought that this change will reduce not only
cases of overdiagnosis, but also false-positives and unnecessary
biopsies (31). We think that this same sort of reconsideration is
also necessary for the handling of ultrasonography findings.
There is also a need to investigate the role of age, but we have
not done this here because of the small sample size. Even if DCIS
were to develop into IDC, it would take a considerable number of
years, and it will be necessary to increase the number of cases and
investigate this in the future.
Moreover, recent research has shown that there are harmful
cases even among IDC (32). Wells et al. reported that 30% of IDC
cases are ultra- low risk (33). It will be necessary to identify harmful
IDC and elucidate its characteristic imaging findings so that it will
be possible to construct an effective screening system for high-
risk cases.
CONCLUSION
Our investigation of the grade of DCIS by using the Ki67 index
as an indicator elucidated that the ER(+)/HER2(-) type is signifi-
cantly lower in its degree of malignancy compared with the other
types of DCIS. Within that type, cases without comedo necrosis
showed significantly lower malignancy than cases with comedo
necrosis, and it was considered to be the least malignant form of
DCIS (LGD). The imaging findings characteristic of LGD were
absence of MC in the MMG findings, and, in the ultrasound find-
ings, either the presence of a solid mass or cystic lesion, or the
absence of hypoechoic areas. However, the sample size of this
study was small, and it will be necessary to analyze a larger number
of cases. There is an urgent need to proceed with this research
in order to reduce the harm caused by breast cancer screening.
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